Oxybutynin chlorideOxybutynin chloride
MedChemExpress (MCE)
HY-B0267A
1508-65-2
99.15%
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months
-20°C, 1 month (sealed storage, away from moisture)
Room temperature in continental US
may vary elsewhere.
Oxybutynin chloride is an oral active and competitive mAChR antagonist with Kis of 14.3 and 5.55 nM for specific [3H]NMS binding in the mouse bladder and cerebral cortex, respectively. Oxybutynin chloride inhibits vascular Kv channels in a manner independent of anticholinergic effect, with an IC50 value of 11.51 μM. Oxybutynin chloride reduces muscle spasm in the bladder and urinary tract, can be used in study of overactive bladder syndrome (OAB). Oxybutynin (chloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Oxybutynin chloride (0.1, 0.3, 1, 3, 10, 30, 100 μM
200 ms) inhibits vascular Kv channels in a concentration-dependent manner independent of anticholinergic effect in coronary arterial smooth muscle cells[1].
Oxybutynin chloride (27.2 mg/kg
p.o.
single) exhibits significant binding of mouse brain muscarinic receptors that about a 2-fold increase in Kd values for specific [3H]N-methylscopolamine binding 0.5 and 2 h later[2].
| | | |
| | | | | |
[1]. Li H, et al. The anticholinergic drug oxybutynin inhibits voltage-dependent K+ channels in coronary arterial smooth muscle cells. Clin Exp Pharmacol Physiol. 2019 Nov
46(11):1030-1036. [Content Brief]
[2]. Oki T, et al. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb
177(2):766-70. [Content Brief]